An­oth­er Avastin biosim­i­lar joins the par­ty as Roche's grip on the mar­ket loosens

Avastin has at­tract­ed quite the crowd of biosim­i­lars in re­cent years, and one more phar­ma com­pa­ny has el­bowed its way in.

Reg­u­la­tors on Wednes­day ap­proved Cell­tri­on’s biosim­i­lar Veg­zel­ma in six can­cer types, in­clud­ing metasta­t­ic col­orec­tal can­cer; re­cur­rent or metasta­t­ic non-squa­mous non-small cell lung can­cer (nsNSCLC); re­cur­rent glioblas­toma; metasta­t­ic re­nal cell car­ci­no­ma; per­sis­tent, re­cur­rent, or metasta­t­ic cer­vi­cal can­cer; and ep­ithe­lial ovar­i­an, fal­lop­i­an tube or pri­ma­ry peri­toneal can­cer.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.